SCHOTT Pharma has announced plans to open a new manufacturing facility in Wilson, North Carolina. The company, which specializes in pharmaceutical drug containment solutions and delivery systems, will use the plant to produce prefillable polymer syringes. These syringes can be used for the storage and transportation of mRNA medications and GLP-1 therapies. SCHOTT Pharma will invest $371 million into the project, creating 401 new jobs for the area. The new facility is expected to help the company triple its contribution of glass and polymer syringes to the U.S. market by 2030. Production at the new plant is expected to begin in 2027.
In a recent quote, Andreas Reisse, CEO of SCHOTT Pharma, said, “As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the U.S. The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”
Investing in American Manufacturing - 2024
This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.